NCT05967156Completed
Empagliflozin in Heart Failure Dialysis Patients
Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients
Source: ClinicalTrials.gov · Last updated 6 Jun 2025
Brief summary (registry, in English)
Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 15 Jul 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Shahid Beheshti University of Medical Sciences
- Diseases
- Heart failure
- NCT number
- NCT05967156
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 1 Jun 2023 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Dialysis patients with no residual urine
Who the study is looking for
- Heart failure on dialysis with residual renal function
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nooshin Dalili Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.